NASDAQ: NEXI - NexImmune, Inc.

Rentabilität für sechs Monate: -99.97%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan NexImmune, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen NexImmune, Inc.

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

weitere details
The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-02-12
ISIN US65344D1090
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.neximmune.com
Цена ао 0.0001
Preisänderung pro Tag: 0% (0.0001)
Preisänderung pro Woche: 0% (0.0001)
Preisänderung pro Monat: 0% (0.0001)
Preisänderung über 3 Monate: -99.93% (0.14)
Preisänderung über sechs Monate: -99.97% (0.33)
Preisänderung pro Jahr: -100% (3.15)
Preisänderung über 3 Jahre: -100% (4.12)
Preisänderung seit Jahresbeginn: -99.96% (0.232)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0.6519 10
P/E 0 0
EV/EBITDA 0.03 10
Gesamt: 5

Effizienz

Name Bedeutung Grad
ROA, % -376.36 0
ROE, % -921.57 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0024 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 38.08 5
Rentabilität EPS, % -21.5 0
Gesamt: 3.8
Weitere Details

Institutionen Volumen Aktie, %
Slate Path Capital, LP 37000 0.27
Adage Capital Partners GP L.L.C. 32055 0.23
Allen Operations LLC 25437 0.18
EPIQ Capital Group, LLC 15624 0.11
PNC Financial Services Group, Inc. 12640 0.09
First Manhattan Company 5964 0.04
M28 Capital Management LP 5338 0.04
Geode Capital Management, LLC 4326 0.03
Vanguard Group Inc 3893 0.03
Comerica Bank 3257 0.02



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. John Trainer M.B.A. Consultant 1.33M 1974 (51 Jahr)
Dr. Daniel P. Bednarik Senior Vice President of Molecular Engineering & Protein Design N/A
Dr. Robert Douglas Knight M.D. Chief Medical Officer 454.77k 1951 (74 Jahr)
Mr. Chad Rubin Senior Vice President of Corporate Affairs N/A
Dr. Jack A. Ragheb M.D., Ph.D. Senior Vice President of Translational Science N/A
Mr. Matthew Schiller Head of Business Development N/A
Mr. Craig R. Jalbert CIRA President, Treasurer, CS, Principal Executive Officer, Financial Off, & Principal Accounting Off 1962 (63 Jahr)
Ms. Karen Haslbeck Head of Human Resources

Adresse: United States, Gaithersburg. MD, 9119 Gaither Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.neximmune.com